Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adintrevimab (ADG20) for mild or moderate COVID-19 (STAMP)
NCT04805671Phase 3Terminated
- Sponsor
- Invivyd
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of adintrevimab in coronavirus disease 2019 (COVID-19), sponsored by Invivyd. Started Jul 2021; status: terminated.
02
Drugs
adintrevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04805671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805671.